Literature DB >> 14469313

Desmethylimipramine (G-35020) in the treatment of depression, pilot study in a general hospital and outpatient setting.

A M MANN.   

Abstract

Entities:  

Keywords:  DEPRESSION/therapy; IMIPRAMINE/related compounds

Mesh:

Substances:

Year:  1962        PMID: 14469313      PMCID: PMC1848943     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


× No keyword cloud information.
  5 in total

1.  The treatment of depressive conditions with imipramine (G 22355).

Authors:  H E LEHMANN; C H CAHN; R L DE VERTEUIL
Journal:  Can Psychiatr Assoc J       Date:  1958-10

2.  Clinical findings in the use of tofranil in depressive and other psychiatric states.

Authors:  B POLLACK
Journal:  Am J Psychiatry       Date:  1959-10       Impact factor: 18.112

3.  [Paper chromatographic determination of metabolic products of tofranil].

Authors:  B HERRMANN; W SCHINDLER; R PULVER
Journal:  Med Esp       Date:  1959

4.  Imipramine; a potent new anti-depressant compound.

Authors:  H AZIMA; R H VISPO
Journal:  Am J Psychiatry       Date:  1958-09       Impact factor: 18.112

5.  Clinical experience with imipramine (G22355) in the treatment of depression.

Authors:  A M MANN; A S MACPHERSON
Journal:  Can Psychiatr Assoc J       Date:  1959-01
  5 in total
  3 in total

1.  PSYCHOPHARMACOLOGY OF IMIPRAMINE AND DESIPRAMINE: A COMPARATIVE STUDY OF THEIR EFFECTS IN NORMAL MALES.

Authors:  A DIMASCIO; G HENINGER; G L KLERMAN
Journal:  Psychopharmacologia       Date:  1964-04-03

2.  [DESIPRAMINE (PERTOFRAN) IN THE TREATMENT OF DEPRESSIONS WITH A PSYCHODYNAMIC ANALYSIS OF ITS THERAPEUTIC EFFECTS].

Authors:  R ALNAES; J KRISTIANSEN
Journal:  Arch Psychiatr Nervenkr       Date:  1964-03-16

3.  [ON THE METHODOLOGY OF RESEARCH ON ANTIDEPRESSIVE DRUGS WITH SPECIAL REFERENCE TO IMIPRAMINE (TOFRANIL) AND DESMETHYLIMIPRAMINE (PERTOFRAN)].

Authors:  H J HAASE; H KOESTER; M KOENIG; A BLEKER
Journal:  Arch Psychiatr Nervenkr       Date:  1963-09-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.